EHRA 2023: Late-Breaking Science Video Collection
Published: 18 April 2023
2m 38sPart 1 | Session 5 TEMPO-HCM: Extended ECG Monitoring in HCM
3m 37sPart 1 | Session 6 Conformable PVI Catheter for Pulmonary Vein Isolation
3m 54sPart 1 | Session 7 BRUGADA Randomized: Epidcardial Ablation to Prevent Sudden Death
6m 25sPart 2 | Session 1 5 Trials That Will Change Your Practice With Dr Sohaib
6m 24sPart 2 | Session 2 4 Trials That Will Change Your Practice With Dr Di Biase
54sPart 3 | Session 1 Dr Bergonti: Pulsed-Field Ablation & Reasons to Research
1m 52sPart 3 | Session 2 Dr Bruce Wilkoff: Therapy Morbidity and Advice to Young Researchers
31sPart 3 | Session 3 Dr Carlo Pappone: Advice to Early-Career Electrophysiologists
28sPart 3 | Session 4 Dr Juan Caro Codon: Building a Team For Success
4m 23sPart 1 | Session 1 POTTER: Oesophageal Fistulae in Catheter Ablation Patients Roland R Tilz
4m 26sPart 1 | Session 2 AdaptResponse: AdaptivCRT® Algorithm in Synchronized LV Pacing Bruce Wilkoff
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research and clinical practice.
More from this programme
In these concise overviews, selected faculty provide their thoughts on the most impactful trials from EHRA 2023.
Behind the Heart
Watch our Behind the Heart series to learn more about the personal perspectives of the investigators behind top trials in cardiovascular science.
About the episode
EHRA 2023 — Join us as we dive into the latest research with investigator, Dr Vivek Reddy (Mount Sinai Hospital, New York, NY, US). He discusses the findings from the MANIFEST-PF registry, adding insights to the evolving landscape of pulsed-field ablation.
The trial studied the use of the Pentaspline PFA Catheter in patients with paroxysmal or persistent atrial fibrillation in order to understand how the device is being used in clinical practice and its outcomes. 24 centers were involved in the trial, with 1500 patients participating.
- What is the current evidence on the use of the pentaspline PFA catheter?
- Please describe the study design of MANIFEST-PF.
- Please provide an overview of the cohort enrolled in MANIFEST-PF.
- What are the key findings from MANIFEST-PF?
- What are some of the unknowns around PFA? What are the promises of this technology?
- What are the planned next steps or future directions based on the findings from MANIFEST-PF?
Recorded on-site at EHRA 2023, Barcelona.
Director of Cardiac Arrhythmia Services
Dr Vivek Y. Reddy is Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and Director of Electrophysiology for the Mount Sinai Health System, and The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at the Icahn School of Medicine at Mount Sinai.
Dr Reddy is one of the US's premier cardiac electrophysiologists. He leads a team of physician-scientists who are developing and testing advanced therapies for cardiac arrhythmias and heart failure, including catheter ablation for atrial fibrillation and ventricular tachycardia, and device therapies for stroke prevention. Under his leadership, Mount Sinai is the lead investigational site for many multinational clinical trials exploring new arrhythmia procedures and technologies, most recently pulsed field ablation to treat atrial fibrillation. Moreover, in 2014, he implanted the world’s first miniature leadless pacemaker, as well as the first leadless pacemaker in…